GlassScriptPhysician profile
Ethel Clemente
NPI 1497986731
$2,724.32
in general payments reported to CMS, 2019-2025
28 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.99 · 2021: $18.16 · 2022: $393 · 2023: $536 · 2024: $740 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,255 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.29 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $388.38 | 2022-2025 | Briviact, Nayzilam, Fintepla |
| Regeneron Healthcare Solutions, INC. | $274.40 | 2022-2024 | Dupixent |
| Novo Nordisk INC | $257.80 | 2022-2025 | Sogroya, Wegovy |
| Ascendis Pharma Endocrinology INC | $246.40 | 2023-2025 | Skytrofa |
| Abbvie INC. | $229.68 | 2019-2025 | Lupron Depot |
| Tolmar, INC. | $191.82 | 2023-2025 | Fensolvi |
| Azurity Pharmaceuticals, INC. | $170.30 | 2023-2025 | Triptodur, Eprontia, Zonisade |
| Kyowa Kirin, INC. | $129.55 | 2023-2025 | Crysvita |
| Sanofi-Aventis U.S. LLC | $123.85 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $78.25 | 2021-2025 | Gvoke Hypopen |
| Acadia Pharmaceuticals INC | $73.34 | 2025 | Daybue |
| Soleno Therapeutics, INC. | $53.86 | 2025 | Vykat Xr |
| Qol Medical, LLC | $52.10 | 2022-2025 | Sucraid |
| Alexion Pharmaceuticals, INC. | $48.31 | 2022-2023 | Strensiq |
| Tandem Diabetes Care, INC. | $39.75 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $39.58 | 2022-2023 | |
| Pfizer INC. | $38.56 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $38.53 | 2022-2025 | |
| Aquestive Therapeutics, INC. | $37.95 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $35.82 | 2022 | |
| Aucta Pharmaceuticals, INC. | $34.14 | 2024-2025 | Motpoly Xr |
| Baxter Healthcare | $25.53 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $22.11 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $20.77 | 2025 | Imcivree |
| Neurelis, INC. | $20.66 | 2022 | |
| Mirum Pharmaceuticals, INC. | $19.57 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.09 | 2024 | |
| Cranial Technologies, INC | $14.22 | 2025 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethel Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.